GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday, Zacks.com reports.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

A number of other equities research analysts have also recently commented on the stock. ValuEngine cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. BidaskClub cut shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Tuesday, September 10th. Finally, JPMorgan Chase & Co. raised shares of GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $22.50 in a report on Thursday, June 27th. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $20.75.

Shares of NASDAQ GRFS traded down $0.20 during midday trading on Monday, reaching $20.11. The company’s stock had a trading volume of 1,039,163 shares, compared to its average volume of 1,153,631. GRIFOLS S A/S has a 12-month low of $17.42 and a 12-month high of $23.03. The firm has a 50 day moving average price of $21.59 and a 200-day moving average price of $20.10. The stock has a market capitalization of $13.83 billion, a P/E ratio of 17.19, a PEG ratio of 1.28 and a beta of 1.11. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.68 and a quick ratio of 0.95.

GRIFOLS S A/S (NASDAQ:GRFS) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.38 billion. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.88%. On average, equities analysts predict that GRIFOLS S A/S will post 1.23 EPS for the current year.

Several large investors have recently bought and sold shares of the stock. Atria Investments LLC raised its holdings in shares of GRIFOLS S A/S by 3.6% in the 2nd quarter. Atria Investments LLC now owns 21,033 shares of the biotechnology company’s stock worth $460,000 after purchasing an additional 734 shares during the period. Mackenzie Financial Corp bought a new stake in shares of GRIFOLS S A/S in the 2nd quarter worth approximately $16,929,000. Royal Bank of Canada raised its holdings in shares of GRIFOLS S A/S by 6.2% in the 2nd quarter. Royal Bank of Canada now owns 190,316 shares of the biotechnology company’s stock worth $4,016,000 after purchasing an additional 11,128 shares during the period. UBS Group AG raised its holdings in shares of GRIFOLS S A/S by 27.0% in the 2nd quarter. UBS Group AG now owns 1,322,161 shares of the biotechnology company’s stock worth $27,898,000 after purchasing an additional 280,695 shares during the period. Finally, Nuveen Asset Management LLC bought a new stake in shares of GRIFOLS S A/S in the 2nd quarter worth approximately $1,854,000. 17.91% of the stock is currently owned by institutional investors.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Article: Different Types of Derivatives

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.